News

                        Array
(
    [0] => stdClass Object
        (
            [id] => 1283
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 6fdf64481b82aadcf393.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-11
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-11 10:47:49
            [updated_time] => 2025-03-12 15:11:13
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/xet-nghiem-sperm-dna-giai-phap-hieu-qua-giup-bac-si-chan-doan-vo-sinh-nam-d1283
            [title] => Sperm DNA Test - An effective solution to help doctors diagnose male infertility
            [description] => In recent years, infertility has been increasing and tends to be younger in the age of the disease. Many statistics show that the cause of infertility due to men is about 40%, equivalent to the infertility rate in women. Therefore, Sperm DNA is considered an important test for doctors in diagnosing and developing the best treatment regimen for infertile men.
            [content] => 
What is Sperm DNA test?
Sperm DNA is a test that quantifies the rate of broken sperm DNA based on the color change of the dye through the flow cytometry system (Analyzing up to 10,000 sperm). Therefore, Sperm DNA is used as an important additional test in predicting male fertility, supporting the determination of the cause of infertility.

GENTIS's Sperm DNA test helps doctors comprehensively assess the patient's sperm quality
This test helps doctors better screen for cases of unexplained infertility. From there, they can orient appropriate intervention treatment (choosing assisted reproductive methods) to shorten time, costs and increase the chance of having children for couples.
The significance of Sperm DNA testing for male doctors
In an interview, Associate Professor, Dr. Le Minh Tam (Hue University of Medicine and Pharmacy) said: “Male infertility is a matter of great concern recently. For a long time, the methods of assessing male infertility were mainly based on semen analysis. However, the semen analysis method only shows the quantity, mobility density, survival rate... but does not show the internal nature of the sperm. Therefore, tests that describe the nature of the internal nature of the sperm are very meaningful”.
Associate Professor, Dr. Nguyen Quang (President of the Vietnamese Society for Sexual Medicine) shared: “Testing for male infertility is very important. It helps male doctors know the specific causes of male infertility, thereby having a specific direction for treatment for patients”.
Understanding this, GENTIS has researched and launched the Sperm DNA test to support a comprehensive assessment of sperm quality. This is an extremely necessary test for male doctors because:

Helps determine the cause of infertility in men in cases where the semen analysis results are normal.
Explains the phenomenon of consecutive miscarriages, unexplained infertility and IVF failure in couples.
Comprehensive assessment of sperm quality through Sperm DNA testing is extremely necessary to predict fertility and have the most appropriate intervention (choosing a reproductive support method).

Who needs to do the Sperm DNA test?
Sperm DNA testing helps determine the cause of male infertility in cases where the semen analysis results are normal
According to GENTIS experts, men should do Sperm DNA testing if they are in the following cases:

Unexplained male infertility or the cause is unclear.
Recurrent miscarriages.
Clinical symptoms of varicocele.
Lifestyle-related risk factors.
Before or after failure of assisted reproductive methods (ART) such as IUI, IVF, ICSI.
Recurrent miscarriages after ICSI.

GENTIS - The most prestigious Sperm DNA testing unit today
In Vietnam, GENTIS is increasingly affirming its pioneering position in the field of genetic analysis of male infertility by researching and developing new tests. Outstanding advantages of Sperm DNA testing at GENTIS are:

Modern technology: Analysis on the Flow cytometry system (analyzing up to 10,000 sperm). The advantages of the Flow cytometry system are stability, accuracy and high performance in Sperm DNA testing
Automated, fast process
Result return time: 24 hours
Cost: Most reasonable, bringing Sperm DNA testing to all men

With ISO standards and working processes along with a team of leading experts in genetics and highly specialized biotechnology, GENTIS is committed to providing customers with quality Sperm DNA testing, affordable prices, and the most professional services. In particular, Sperm DNA testing supports well in diagnosing genetic factors in male infertility, thereby helping doctors to develop appropriate treatment regimens, overcoming infertility in men.
GENTIS is a pioneer in the field of genetic analysis, specializing in providing tests with the highest accuracy
In addition to Sperm DNA, to evaluate and find the cause of male infertility, GENTIS also provides many specialized tests to help doctors provide appropriate treatment. These include Karyotype testing, hormone testing, sperm DNA fragmentation, AZF testing, anti-sperm antibody testing, sperm chromosome aneuploidy testing, STDs testing, etc.
With a team of leading experts in genetics and biotechnology with high professional qualifications and the most modern facilities and technology, GENTIS is committed to providing tests with the highest accuracy. Thereby contributing to realizing the dream of becoming parents of infertile couples.
            [content_more] => 
            [meta_title] => Sperm DNA Test - An effective solution to help doctors diagnose male infertility
            [meta_description] => Sperm DNA is considered an important test for doctors in diagnosing and developing the best treatment regimen for infertile men.
            [meta_keyword] => gentis,sperm dna
            [thumbnail_alt] => 
            [post_id] => 1283
            [category_id] => 4
        )

    [1] => stdClass Object
        (
            [id] => 1281
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => af39d43f63cfdd9184de.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-02-24
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-02-24 09:14:22
            [updated_time] => 2025-03-06 11:18:33
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/me-bau-nao-nen-thuc-hien-xet-nghiem-sang-loc-truoc-sinh-nipt-d1281
            [title] => Which pregnant women should do Non-invasive prenatal testing?
            [description] => NIPT (Non-invasive prenatal testing) is a method of prenatal screening for pregnant women before giving birth. This prenatal screening method is often chosen because of its non-invasive advantages, helping to detect many congenital malformations in the fetus early, thereby helping pregnant women to manage their pregnancy effectively.
            [content] => 
Who is NIPT suitable for?
With the common mentality of pregnant women being worried about the development and wanting the best care for the fetus, pregnant women always want to look for prenatal testing methods to check the health of the fetus. NIPT testing is recommended for pregnant women in the first 3 months and the middle 3 months of pregnancy, especially for those at high risk:

Pregnant women over 35 years old
According to research by experts, the quality of eggs in women after 35 years old decreases, directly affecting the embryo. Therefore, the fetus is at high risk of chromosomal disorders and is at risk of Down's, Edward's, Patau's syndrome...
In addition, women over 35 years old are often prone to problems such as uterine fibroids, endometriosis... when pregnant, their health declines, hormonal changes make the disease worse, leading to an increased risk of fetal malformations.

Family history of genetic diseases
Studies show that fetal malformations can be passed down from parents to children. If the family has parents-in-law, parents-in-law, or siblings with genetic diseases, the fetus is at high risk of malformations. Although there is no exact research on the percentage, pregnant mothers should also be screened before birth, especially by performing NIPT testing to be able to take good care of the fetus.
Pregnant women who undergo assisted reproductive techniques
The risk of birth defects in children born through artificial insemination is much higher than in children born naturally, even when maternal factors are controlled. Therefore, mothers who undergo this method are advised by doctors to use the NIPT test method.
Biochemical and ultrasound results - high-risk nuchal translucency measurement
History of pregnancy with malformations, unexplained stillbirths or giving birth to children with congenital malformations
Steps to perform NIPT testing

Step 1: Get advice from a doctor
Before taking a sample, the pregnant woman will be informed about the basic information of the NIPT test. Depending on the condition and finances of the pregnant woman, the doctor will advise on appropriate packages. Accompanying pregnant mothers on the path to reproductive health care, GENTIS provides a variety of NIPT prenatal screening service packages

 Genbasic

- Detects aneuploidy on 3 common chromosomes: Down, Patau, Edward
- Applicable for single and twin pregnancies
- Time to return results: 4 - 5 days

 Genbasic Plus

- Detects 5 syndromes: Edwards, Patau, Down, Turner (XO), Klinefelter (XXY)
- Applicable for single and twin pregnancies
- Time to return results: 4 - 5 days

 GenEva

- Detects 8 syndromes: Edwards, Patau, Down, Turner (XO), Klinefelter (XXY), trisomy (XXX), Jacobs (XYY) and detects quantitative abnormalities on all remaining chromosomes
- Applicable for single and twin pregnancies
- Time to return results: 4 - 5 days

 GenEva Plus

- Detects all all types of abnormalities in the GenEva package. At the same time, the package also detects 86 microdeletion mutations
- Applicable for single and twin pregnancies
- Time to return results: 4 - 5 days
Step 2: Take blood for NIPT screening test
Take 7-10ml of blood from the pregnant woman's arm vein for testing.
Step 3: Transfer the blood sample to the GENTIS testing center for analysis.
Step 4: Receive results after 4 - 5 days from the date of sample collection.
Step 5: After receiving the results, the doctor will analyze and advise on appropriate fetal care methods, especially in cases of genetic diseases.
Advantages of performing NIPT testing at GENTIS

High accuracy
NIPT testing is considered more accurate than traditional screening. NIPT prenatal screening is based on DNA genetic material, so it is not affected by environmental factors. In addition, the method is also performed by analyzing the new generation gene sequencing algorithm with a high-tech equipment system with an accuracy rate of over 99%.
Fast results
The test result return time is about 4 - 5 days after sample collection. The sample analysis time by machine is fast, helping NIPT test return results in the shortest time.
Safe
The test sample is the mother's blood, so the prenatal screening method does not cause any negative effects on both mother and baby. Because the test only takes 7-10ml of the mother's blood to separate extracellular DNA, then sequence the DNA and analyze.
Applicable in many cases
NIPT testing is applicable to cases of pregnant mothers with single, twin, and multiple pregnancies.
Screening and detecting diseases related to abnormal chromosomes is extremely good.
NIPT GENTIS test accompanies parents on the journey to welcome their beloved children. Contact hotline: 1800 2010 to schedule a consultation and NIPT test at GENTIS.
            [content_more] => 
            [meta_title] => Which pregnant women should do Non-invasive prenatal testing?
            [meta_description] => NIPT (Non-invasive prenatal testing) is a method of prenatal screening for pregnant women before giving birth.
            [meta_keyword] => gentis,Nipt
            [thumbnail_alt] => 
            [post_id] => 1281
            [category_id] => 4
        )

    [2] => stdClass Object
        (
            [id] => 1280
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => b1fcf6d2f5e24bbc12f3.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-02-19
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-02-19 10:58:57
            [updated_time] => 2025-03-21 15:13:16
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/gentis-ra-mat-2-goi-xet-nghiem-phan-tich-di-truyen-truoc-chuyen-phoi-moi-pgt-next-va-pgt-upgrade-d1280
            [title] => GENTIS launches 2 new test packages: PGT NEXT and PGT UPGRADE
            [description] => With the pioneering advantage in applying genetic and genetic testing in assisted reproduction, GENTIS constantly strives to improve and launch new expanded pre-implantation genetic testing packages: PGT NEXT and PGT UPGRADE. These are two superior in-depth integrated tests with many outstanding advantages.
            [content] => 

PGT NEXT
PGT NEXT is a pre-implantation genetic analysis test that can detect aneuploidy on 24 chromosomes, chromosomal abnormalities, and chromosomal deletions. It can also detect embryos with polyploidy or haploidy. This helps avoid transferring polyploid/haploidy abnormal embryos, and avoid wasting euploid embryos with fertilization abnormalities (0PN, 1PN, and 2.1/3PN). In addition, the PGT NEXT test also supports the provision of genetic information for embryo selection before embryo transfer. The combination of NGS whole genome sequencing with SNP analysis improves the resolution of genetic screening for polyploidy.This method allows for the identification of haploid and polyploid chromosome sets, increasing the number of healthy euploid embryos available for transfer by accurately detecting true diploid embryos among abnormally fertilized embryos (0PN, 1PN, 2.1PN, 3PN). Additionally, SNP analysis ensures precise identification of whether the tested embryo is genetically related to other embryos in the same cohort, thereby reducing the risk of sample mix-ups due to procedural or handling errors.


 Detection range:

- Aneuploidy of all 24 chromosomes
- Chromosomal structural abnormalities (addition, deletion)
- Detection of embryos with polyploidy or haploid abnormalities.

 Method: Whole genome sequencing and target marker sequencing on next-generation sequencing machine NGS.
 Sample used: Day 5 embryo biopsy sample
 Time to return results: 3 – 4 weeks

PGT UPGRADE
PGT UPGRADE is a pre-implantation genetic analysis test that can detect aneuploidy on 24 chromosomes, additional abnormalities, chromosomal deletions with a size of over 5 Mb, especially capable of detecting embryos carrying balanced translocations inherited from the parents. Chromosomal translocations are structural abnormalities of chromosomes caused by the rearrangement of large segments between non-homologous chromosomes. There are two types of translocations: balanced (no loss of genetic material) and unbalanced (loss or extra genetic material, such as aneuploidy). When both the father and mother carry balanced translocations, approximately 60% of gametes will carry unbalanced translocations, leading to embryos with chromosomal abnormalities. This is also a common cause of repeated implantation failure, recurrent miscarriage, and birth defects. PGT UPGRADE test helps to select euploid embryos for parents carrying balanced translocations to increase the chance of having a healthy baby. In addition, PGT UPGRADE also supports providing genetic information for the embryo selection process before embryo transfer.
Performing PGTest testing can select genetically good quality embryos to increase the chance of pregnancy when performing in vitro fertilization (IVF), helping to increase the chance of the child being born healthy, without the screened genetic abnormalities.


 Detection range:

- Aneuploidy of all 24 chromosomes
- Chromosomal structural abnormalities (addition, deletion) larger than 5 Mb
- Detection of embryos carrying balanced genetic translocations inherited from parents

 Method: Next generation sequencing NGS (Illumina) and analysis of sequencing results using specialized bioinformatics software
 Samples used:

- Parental samples (2-3 ml whole blood in EDTA anticoagulant tubes) and balanced translocation test results.
- Day 5 embryo biopsy sample

 Time to return results: 12 - 14 days

Meaning of PGT NEXT and PGT UPGRADE tests
Preimplantation Genetic Testing (PGT) is a specialized technique to identify genetic abnormalities in embryos created through in vitro fertilization (IVF/ICSI). Preimplantation genetic testing offers the following benefits:
Detecting genetic abnormalities in embryos
PGT helps identify abnormalities in chromosome number (PGT-A) or specific gene mutations (PGT-M), thereby reducing the risk of passing on genetic diseases to the next generation.
Increase IVF success rate
Selecting healthy embryos with normal genes improves implantation rates, increases the chance of pregnancy, and reduces the risk of miscarriage.
Support for optimal embryo selection
Ensuring that only embryos that do not carry genetic diseases or genetic abnormalities are transferred into the uterus increases the chances of having a healthy baby.
Advanced and modern technology
Illumina's next-generation sequencing technology (NGS) with >99% accuracy on target markers and specialized bioinformatics software is the technological standard for PGT testing, increasing the accuracy and sensitivity of the test.
Currently, preimplantation genetic testing (PGT) packages can be performed at a number of hospitals and reproductive support centers in Vietnam. Among them, GENTIS is a pioneer in performing PGT testing packages accurately and professionally.
In particular, GENTIS has a system of high-tech machinery and a team of experienced professionals, where infertile couples put their trust when performing difficult tests. Before doing the screening test, customers will be given genetic counseling and detailed information about the test. Through PGT testing packages, GENTIS hopes to support doctors and infertile couples to quickly find their beloved children, as well as give birth to healthy children, bringing happiness to families nationwide.
            [content_more] => 
            [meta_title] => GENTIS launches 2 new test packages: PGT NEXT and PGT UPGRADE
            [meta_description] => GENTIS constantly strives to improve and launch new expanded pre-implantation genetic testing packages: PGT NEXT and PGT UPGRADE.
            [meta_keyword] => gentis,Pgt,Pgtnext,Pgtupgrade
            [thumbnail_alt] => 
            [post_id] => 1280
            [category_id] => 4
        )

    [3] => stdClass Object
        (
            [id] => 1275
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => gentis-11.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2025-01-14
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-01-14 10:08:21
            [updated_time] => 2025-01-14 10:16:28
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Breakthroughs-in-the-application-of-genetic-testing-in-reproductive-medicine-worldwide-and-in-Vietnam
            [title] => Breakthroughs in the Application of Genetic Testing in Reproductive Medicine Worldwide and in Vietnam
            [description] => During her visit and work in Vietnam, Assoc. Prof. Dr. Francesca Spinella (Senior Medical Information Specialist at Eurofins Genoma Group, Former President of ESHRE PGT Consortium) expressed her admiration for the remarkable advancements made by genetic testing laboratories in the diagnosis and treatment within the field of reproductive medicine. In particular, she praised GENTIS for both its professional expertise and state-of-the-art facilities. She mentioned that the collaboration between GENTIS and GENOMA will enhance multi-level development among global healthcare organizations, particularly in the area of genetic testing.
            [content] => 
Genetic Breakthroughs in Preimplantation Genetic Testing Being Applied in Europe and Vietnam
Assoc. Prof. Dr. Francesca Spinella explained that there are currently three widely used preimplantation genetic testing techniques being applied across Europe and globally: PGT-A, PGT-SR, and PGT-M. These primary methods help improve the success rates of in vitro fertilization (IVF) while reducing the risk of serious genetic disorders in future generations.
Among these, PGT-A helps detect chromosomal aneuploidy to screen out embryos that have abnormalities. This method has been proven to increase IVF success rates, decrease miscarriage rates, and ensure that the embryos implanted are the healthiest.
PGT-M is used to detect genetic mutations that could be inherited from parents, helping to avoid passing on common monogenic disorders like thalassemia, cystic fibrosis, Huntington's disease, and other genetic conditions. PGT-SR can detect structural chromosome abnormalities such as translocations, inversions, or deletions. These abnormalities can cause pregnancy complications and increase the risk of giving birth to a child with birth defects.
In addition to the widely implemented techniques, Assoc. Prof. Dr. Francesca Spinella mentioned two promising new methods that are being researched and developed in Europe: Non-invasive PGT-A (NiPGT-A) and PGT for ploidy (Ploidy). These breakthroughs are driven by the rapid development of genetic sequencing technologies, opening new possibilities for reproductive healthcare.
NiPGT-A represents a breakthrough in preimplantation genetic testing, allowing for testing without the need for embryo biopsy, thus minimizing potential risks to the embryo. This method detects chromosomal abnormalities in embryos from the culture medium, providing greater convenience and safety. Meanwhile, PGT for ploidy (Ploidy) is an advanced test that accurately determines the number of chromosomes in the embryo, helping to select embryos with a complete chromosomal set, thereby reducing the risk of reproductive issues or birth defects.
Assoc Prof. Dr. Francesca Spinella also expressed her deep impression with the preimplantation genetic testing methods being used in Vietnam. She stated that the expertise and modern facilities of the labs, especially at GENTIS, are on par with leading genetic testing centers worldwide.
Assoc Prof. Dr. Francesca Spinella Visits and Works at GENTIS Lab
In addition to common tests like PGT-A, PGT-M, and PGT-SR, GENTIS is also focusing on researching and developing two breakthrough techniques: PGT-Next and PGT-Upgrade. PGT-Next is an advanced method that combines the features of both PGT-A and PGT-SR, with the added capability of detecting chromosomal number abnormalities such as polyploidy and haploidy in embryos. This improves diagnostic accuracy, minimizes the risk of pregnancy with embryos that have chromosomal abnormalities, and optimizes the chances of a healthy pregnancy.
PGT-Upgrade is a significant advancement in genetic diagnosis of embryos. In addition to detecting abnormalities in chromosome number (PGT-A) and structure (PGT-SR), PGT-Upgrade can identify balanced chromosomal translocations passed from parents to embryos. This method helps detect hidden risks that PGT-A and PGT-SR cannot diagnose, while also identifying genetic factors that could affect the health of future generations. PGT-Upgrade offers superior advantages in selecting healthy embryos for artificial reproduction, thereby improving IVF success rates.
Strengthening Relationships and Promoting Multilateral Cooperation Among Global Healthcare Organizations
Promising Collaboration Between GENTIS and GENOMA
Through her visit and discussions, Assoc. Prof. Dr. Francesca Spinella noted that Vietnam’s healthcare services, particularly in reproductive medicine, have significant potential for growth. She emphasized that this event not only provided an opportunity to exchange ideas on advancements in genetic testing but also served as a clear testament to the sustainable and strategic partnership between GENTIS and GENOMA, both members of the Eurofins family. The cooperation between GENTIS and GENOMA is not based solely on commercial interests but also on the shared commitment to scientific research and advanced technologies. Both organizations share values in improving reproductive health and providing accurate and reliable genetic testing services for families and healthcare professionals in their reproductive health journeys.
This collaboration also allows GENTIS to access the latest genetic testing technologies and implement them in Vietnam, enhancing the quality of reproductive healthcare services domestically and contributing to the development of the genetic testing industry in Southeast Asia. GENTIS’s clients will now benefit from advanced genetic testing services, which offer the opportunity for healthy childbirth and minimize risks during pregnancy.

            [content_more] => 
            [meta_title] => Breakthroughs in the Application of Genetic Testing in Reproductive Medicine Worldwide and in Vietna
            [meta_description] => During her visit and work in Vietnam, Assoc. Prof. Dr. Francesca Spinella, she mentioned that the collaboration between GENTIS and GENOMA will enhance multi-level development among global healthcare organizations, particularly in the area of genetic testi
            [meta_keyword] => GENTIS,pgt
            [thumbnail_alt] => 
            [post_id] => 1275
            [category_id] => 4
        )

    [4] => stdClass Object
        (
            [id] => 1274
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => gentis-6.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 0000-00-00
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-01-11 08:29:18
            [updated_time] => 2025-01-13 15:57:55
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => learning-about-new-genetic-tests-in-reproductive-support-worldwide-and-their-application-in-europe-with-assoc-prof-dr-francesca-spinella
            [title] => Learning About New Genetic Tests in Reproductive Support Worldwide and Their Practical Application in Europe with Assoc. Prof. Dr. Francesca Spinella
            [description] => With the goal of updating knowledge to enhance the effectiveness of medical examination and treatment, as well as to introduce reproductive support techniques being applied in Europe, the GENTIS Genetic Counseling Center successfully organized the 5th edition of the Genetic Counseling Talkshow - Discussion with Experts. The theme was “Application of New Genetic and Genomic Testing in Reproductive Support Worldwide and Their Practical Use in Europe.” GENTIS was honored to have Assoc. Prof. Dr. Francesca Spinella (Senior Medical Information Specialist of Eurofins Genoma Group, Former Chair of the ESHRE PGT Consortium) and Dr. ThS. BSNT Đinh Thị Quỳnh Ngọc (GENTIS Genetic Counseling Center) as speakers. The program attracted widespread attention from doctors, specialists, and many audiences interested in reproductive support methods.
            [content] => 
Speaking about the pre-implantation genetic testing (PGT) techniques currently used in Europe, Assoc. Prof. Dr. Francesca Spinella said: "Currently, there are three common types of pre-implantation genetic tests: PGT-A, PGT-SR, and PGT-M. PGT-A is used to detect chromosomal abnormalities, allowing the selection of embryos without chromosomal abnormalities for embryo transfer. PGT-M is a tool to detect genetic mutations that could be inherited from the parents, thereby preventing the transfer of embryos with genetic disorders. PGT-SR is a method capable of detecting structural chromosomal abnormalities of 5Mb or more in embryos, thus increasing the chances of achieving a successful pregnancy by selecting normal embryos."
In addition to the three conventional PGT tests, Assoc. Prof. Dr. Francesca Spinella also discussed two new methods: Non-invasive PGT-A (NiPGT-A) and PGT for Ploidy (Ploidy). “NiPGT-A provides the opportunity to test embryos without the need for biopsy, by analyzing DNA in the culture medium. Meanwhile, PGT for Ploidy helps detect the presence of specific chromosomal abnormalities in embryos, thus avoiding the transfer of these embryos." However, she also mentioned that more research is needed to further validate the effectiveness of these two methods.

Assoc. Prof. Dr. Francesca Spinella also addressed several audience questions, including the importance of genetic counseling in IVF procedures, criteria for selecting mosaic embryos for transfer, and especially the appropriate timing for performing PGT methods, especially PGT for Ploidy. She spent a lot of time discussing the advantages, practical applications, and outcomes that can be achieved by using the genetic testing methods currently applied in Europe.
Understanding the concerns of infertile couples about the cost of these procedures, Assoc. Prof. Dr. Francesca Spinella shared: "The new PGT tests are optimal methods, incorporating advanced techniques from pre-implantation genetic screening. Therefore, it is understandable that the costs of these tests are slightly higher. However, in the future, the cost of these tests may decrease due to rapid technological advancements and the widespread adoption of testing. For example, the first PGT tests had extremely high costs when they were first introduced, but over time, the costs have stabilized, allowing many patients to access this method."
Notably, during the conversation, Assoc. Prof. Dr. Francesca Spinella provided in-depth insights and timely answers, helping doctors, specialists, and viewers better understand the application of current pre-implantation genetic tests. The Talkshow program was a success, attracting thousands of views, numerous shares, and receiving a lot of support from the audience.

Before concluding the Talkshow, Assoc. Prof. Dr. Francesca Spinella shared that she was very impressed after visiting some PGT and IVF labs in Vietnam, particularly GENTIS. She further mentioned that she was impressed with the facilities and the quality of healthcare professionals in Vietnam. Additionally, Assoc. Prof. Dr. Francesca Spinella noted that “Vietnam’s healthcare services in general, and reproductive support in particular, have a lot of potential for development” and emphasized the collaborative relationship within the Eurofins family, both scientifically and commercially.
We hope that the insights shared by the experts during the Talkshow will be beneficial for doctors and the audience. GENTIS Genetic Counseling Center sincerely thanks the doctors, partners, experts, and clients for their participation. We will continue to organize more Genetic Counseling Talkshow programs to provide valuable information to the audience.



            [content_more] => 
            [meta_title] => Learning About New Genetic Tests in Reproductive Support Worldwide and Their Practical Application i
            [meta_description] => With the goal of updating knowledge to enhance the effectiveness of medical examination and treatment, as well as to introduce reproductive support techniques being applied in Europe, the GENTIS Genetic Counseling Center successfully organized the 5th edi
            [meta_keyword] => Gentis,PGT
            [thumbnail_alt] => 
            [post_id] => 1274
            [category_id] => 4
        )

    [5] => stdClass Object
        (
            [id] => 1273
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 461103487_919832673515258_4243371323831293845_n.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2024-12-22
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-01-08 13:49:54
            [updated_time] => 2025-01-09 09:18:38
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Gentis-accompanies-the-Androilogy-and-fertility-hospital-of-hanoi-at-the-5th-Scientific-Conference
            [title] => Gentis accompanies the Andrology and fertility hospital of Hanoiat the 5th Scientific
            [description] => On the morning of September 22, 2024, Hanoi Hospital for Male Health and Infertility (AF HANOI) successfully organized the "5th Scientific Conference." This event is part of a series of activities celebrating the 15th anniversary of the hospital's establishment. The conference provided an opportunity for experts and doctors to discuss the current state of male infertility treatment from practical and diverse perspectives. Additionally, several new research findings were shared by leading specialists and experienced doctors to update effective treatment methods for patients. GENTIS is honored to accompany the Hanoi Hospital for Male Health and Infertility as a sponsor, contributing to the success of the conference.
            [content] => 
The event was attended by esteemed guests, including Prof. Dr. Nguyen Dinh Tao, President of the Hanoi Fertility Support Association; former Deputy Director of the Embryo Technology Center (now the Army Clinical Morphology Institute – Military Medical Academy); Prof. Tran Thi Phuong Mai, former Deputy Head of the Maternal and Child Health Department; Assoc. Prof. Dr. Nguyen Quang, President of the Vietnam Sexual Medicine Association, Director of the Male Health Center, Viet Duc Friendship Hospital, along with nearly 200 delegates who are leading experts and doctors from major hospitals and medical centers across the country. From the Hanoi Hospital for Male Health and Infertility, attendees included: Assoc. Prof. Dr. Le Thi Thu Hien – Medical Director of the Hospital; Dr. CKI Pham Van Huong – Deputy Medical Director, Head of the Assisted Reproductive Technology Department; Assoc. Prof. Nguyen Minh Duc, Head of the Assisted Reproductive Technology Laboratory; and Dr. Dinh Huu Viet - Head of the Male Health Department.

At the 5th Scientific Conference, alongside research presentations from leading experts from major hospitals and fertility centers, such as the report "Male Infertility: Current Challenges and Future Directions" by Assoc. Prof. Dr. Nguyen Quang, and "Disorders of Sexual Development and Reproductive Function" by Assoc. Prof. Dr. Vu Chi Dung, the Hanoi Hospital for Male Health and Infertility contributed three reports on highly practical topics: “Male Infertility from a Practical Perspective at the Hanoi Hospital for Male Health and Infertility” by Dr. Dinh Huu Viet; “Preparation of Severe Abnormal Sperm Samples in Assisted Reproduction” by Assoc. Prof. Nguyen Minh Duc; and “Genetic Testing Before Embryo Transfer in Male Infertility: When is it Necessary?” presented by Dr. Bui Thi Phuong Hoa, a genetics specialist. These three topics were synthesized and researched by doctors and embryologists to share knowledge and gather feedback from leading experts in genetics, male health, and reproductive support. The aim was also to provide new perspectives on male infertility treatment from genetic and embryological aspects in actual clinical practice.
Speaking at the conference, Assoc. Prof. Dr. Le Thi Thu Hien (Medical Director of the Hospital) stated, “In addition to our daily medical examination and treatment activities, the Hanoi Hospital for Male Health and Infertility is particularly focused on scientific research. Scientific research helps create reliable new knowledge, enhances treatment quality and safety for patients, and increases effectiveness at reasonable costs. Moreover, scientific research enables doctors and healthcare staff to continuously improve their knowledge and skills while addressing issues in their professional work, aiming to deliver the best outcomes for patients. We have been and are striving to excel in both medical treatment and scientific research to bring new breakthroughs to our nation's healthcare."

The conference successfully created an open forum for sharing experiences and knowledge. The enthusiastic participation of experts and doctors fostered a vibrant and beneficial discussion space, aiming to find new directions for the field of male health. The hospital expresses sincere gratitude to all speakers and esteemed delegates, experts, and doctors who contributed to the success of this conference.
            [content_more] => 
            [meta_title] => Gentis accompanies the Andrology and fertility hospital of Hanoi at the 5th Scientific Conference
            [meta_description] => On the morning of September 22, 2024, Hanoi Hospital for Male Health and Infertility (AF HANOI) successfully organized the "5th Scientific Conference.".  GENTIS is honored to accompany the Hanoi Hospital for Male Health and Infertility as a sponsor, contr
            [meta_keyword] => Gentis
            [thumbnail_alt] => 
            [post_id] => 1273
            [category_id] => 4
        )

    [6] => stdClass Object
        (
            [id] => 1272
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => Ảnh.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2024-12-09
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-01-08 13:39:57
            [updated_time] => 2025-01-09 09:21:30
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Gentis-accompanies-the-journey-of-spearding-love-at-the-Gala-Seeds of Aspiration
            [title] => GENTIS Accompanies the Journey of Spreading Love at the Gala "Seeds of Aspiration"
            [description] => On the evening of December 7, 2024, the second Gala "Seeds of Aspiration" was successfully held at the Military Broadcasting and Television Center. During the event, the organizers announced and awarded the decision to support 100% of the costs for In Vitro Fertilization (IVF) under the program "Support for Infertile Soldiers - Love Spreads" for 2024 to 10 families of infertile soldiers.
            [content] => 

Immediately after the "Support for Infertile Soldiers - Love Spreads" program was widely announced in the media, many applications from military families were submitted. The expert council from the hospital and the Military Broadcasting and Television Center worked impartially, carefully reviewing each case to grant 10 families free IVF support for 2024.
The 10 selected cases for free IVF will receive 100% coverage of costs, including expenses for testing, egg stimulation, egg retrieval, embryo creation, embryo storage, and embryo transfer.
This year's gala brought a variety of emotions to the audience: from empathy with the unspoken struggles of infertility during the stage interaction with families longing for children, to the joy of finally holding their beloved children after much anticipation, showcased through the artistic program "Tears of Happiness" directed by Meritorious Artist Tu Long and performed by artists from the Military Cheo Theater.

In addition to the selected families for free IVF this year, nearly 30 military families, along with their children born from the first phase of the "Love Spreads" program, were present to inspire hope and trust among their peers, as well as express gratitude to the organizers and the medical staff who made their dreams of parenthood a reality.
The Gala "Seeds of Aspiration" this year was not just an artistic program or a simple ceremony for announcing and granting support, but also a reunion and return home—a place where the happiness of military families flourishes.
It is evident that the stories of military families receiving 100% support for IVF in 2021, 2022, and 2023 serve as a source of motivation for many other couples struggling with infertility on their journey to find their beloved children. The starting point may be incredibly challenging, seemingly leading to a point of giving up, but with love, community support, and perseverance, miracles will eventually come to these families.

GENTIS, wishing to spread the message "giving is everlasting," continues to accompany this year’s program as a sponsor, to provide additional trust and strength to military families. GENTIS hopes that this partnership will help military families remain steadfast on their arduous journey to parenthood. The starting point may be difficult, but with faith, love, and perseverance, miracles will eventually arrive for military families.
Through the Gala "Seeds of Aspiration," GENTIS aims to contribute even more to charitable efforts in the community, spreading the message "giving is everlasting" to collectively build a sustainable society and enhance the physical and intellectual well-being of the Vietnamese people.
            [content_more] => 
            [meta_title] => GENTIS Accompanies the Journey of Spreading Love at the Gala "Seeds of Aspiration"
            [meta_description] => On the evening of December 7, 2024, the second Gala "Seeds of Aspiration" was successfully held at the Military Broadcasting and Television Center. During the event, the organizers announced and awarded the decision to support 100% of the costs for In Vit
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1272
            [category_id] => 4
        )

    [7] => stdClass Object
        (
            [id] => 1271
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => mti09930.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2024-12-30
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2024-12-30 16:32:34
            [updated_time] => 2025-01-02 08:56:29
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 0
            [language_code] => en
            [slug] => Genetic-counseling-and-pgt-testing-from-international-guidelines-to-clinical-practice-in-vietnam
            [title] => Genetic Counseling and PGT Testing: From International Guidelines to Clinical Practice in Vietnam
            [description] => Currently, the demand for Preimplantation Genetic Testing (PGT) among couples at high genetic risk, who wish to have healthy children, is increasing. Preimplantation Genetic Testing (PGT) was developed to screen and detect genetic abnormalities in embryos before they are implanted into the mother’s uterus.
            [content] => 
With advances in technology and testing methods, PGT continues to be developed and clinically validated, thereby improving the success rates of assisted reproductive treatments. This is especially beneficial for parents with genetic diseases, allowing them to have healthy children free from genetic disorders.
According to global publications and studies, using next-generation sequencing (NGS) technology, current PGT tests can screen for and detect abnormalities in chromosome number (aneuploidy) across 23 pairs of chromosomes, known as PGT-A, structural chromosome abnormalities (addition/deletion/duplication), known as PGT-SR, single-gene disorders, known as PGT-M, and recently, some reports have emerged regarding the development of PGT for polygenic diseases (PGT-P). As the use and complexity of preimplantation genetic testing (PGT) increases, genetic counseling has become an essential part of modern medicine. GENTIS successfully organized a scientific seminar on "Genetic Counseling and PGT Testing: From International Guidelines to Clinical Practice in Vietnam."

At the seminar, Specialist Doctor Level 1 Nguyen Van Thong,, Head of the Department of Medical Genetics at Hung Vuong Hospital, explained: "Genetic counseling is a process that provides information, support, and guidance related to genetics and genetic risk factors for individuals or families. It helps assess the likelihood of inheriting genetic diseases based on family history or genetic test results. Additionally, it provides knowledge about genetic-related diseases or conditions, such as cancer, genetic disorders, or congenital abnormalities.
Furthermore, doctors will counsel on the benefits, limitations, and risks of genetic tests to help patients make informed decisions. Once the genetic test results are available, the doctor will explain the results and their implications for personal and family health. In addition, genetic counseling also provides psychological support to help patients and families deal with worries or emotions related to the results or genetic risks. Moreover, doctors will discuss follow-up, treatment, or prevention measures based on genetic risks."

Specialist Doctor Level 1 Nguyen Van Thong, also emphasized the importance of collaboration among genetic specialists, infertility doctors, embryologists, and healthcare workers to ensure the highest efficacy in the testing process. He also shared the role of PGT in supporting couples to have healthy children by screening and detecting genetic abnormalities. Technological advancements in PGT-A/SR and PGT-M not only increase the chances of successful pregnancies but also reduce the risks of miscarriage and serious genetic diseases in the fetus.
From a clinical perspective, Dr. Le Thi Minh Chau, Head of the Infertility Department at Tu Du Hospital, shared that over the past thirty years, there have been rapid advancements in genetic testing and assisted reproductive technology, reshaping the PGT testing process. The development of whole genome amplification (WGA) tools, combined with optimized hormonal stimulation protocols and more effective cryopreservation methods, has led to more accurate diagnoses and improved clinical outcomes. Furthermore, the shift from day 3 to day 5 or early day 6 embryo biopsy has altered the timeline for a typical PGT clinical process.

Although PGT helps reduce pregnancy terminations, in cases such as families with single-gene disorders, PGT is a relevant option for preimplantation genetic diagnosis. However, PGT remains a solution that requires discussion and consensus guidelines. Some of the complexities in the IVF process are especially relevant for couples without fertility issues, including the risk of diagnostic errors, potential embryo damage from invasive procedures, and ethical concerns. Therefore, the decision to undergo PGT is complex and always involves a stressful decision-making process.
Sharing her experience with PGT testing in Europe, Prof. Dr. Francesca Spinella, Senior Medical Information Specialist at Eurofins Genoma Group and Senior Consultant at GENTIS, explained: "Preimplantation Genetic Testing is a growing trend in Europe and globally. PGT analyzes genetic abnormalities (gene level and chromosomal abnormalities) in embryos before transferring them into the mother's uterus, helping to select embryos with a high implantation potential and a good chance of producing a healthy baby. However, in Europe, only reputable tests such as PGT-A, PGT-SR, and PGT-M are accepted and widely monitored by the ESHRE PGT Consortium."
The ESHRE PGT Consortium, founded in 1997, is responsible for collecting data on the accuracy, reliability, efficacy, and safety of PGT-A, PGT-M, and PGT-SR. It also establishes minimum standards and promotes best practice guidelines. Additionally, the Consortium facilitates the exchange of ideas and perspectives among members.
At the seminar, Prof. Dr. Francesca Spinella also introduced new PGT tests being developed at Eurofins Genoma Group. She noted that Eurofins Genoma Group is researching and developing a new PGT testing package called PGT Next. PGT Next, in addition to detecting chromosomal abnormalities such as PGT-A/SR, can also detect aneuploidy, identify euploid embryos without abnormalities, even in cases of embryo morphological abnormalities.
Through the seminar "Genetic Counseling and PGT Testing: From International Guidelines to Clinical Practice in Vietnam," GENTIS hopes that attendees have gained new information and knowledge about preimplantation genetic testing (PGT) and a clearer understanding of the value and applicability of PGT tests in assisted reproduction. This will contribute to improving clinical outcomes, supporting patients in making informed decisions, and increasing the chances of successful pregnancies and healthy babies.
            [content_more] => 
            [meta_title] => Genetic Counseling and PGT Testing: From International Guidelines to Clinical Practice in Vietnam
            [meta_description] => Currently, the demand for Preimplantation Genetic Testing (PGT) among couples at high genetic risk, who wish to have healthy children, is increasing
            [meta_keyword] => GENTIS,pgt
            [thumbnail_alt] => 
            [post_id] => 1271
            [category_id] => 4
        )

)